Loading...
Loading...
PNT| Name | Value |
|---|---|
| Revenues | 226.6M |
| Cost of Revenue | 0.0M |
| Gross Profit | 226.6M |
| Operating Expense | 35.2M |
| Operating I/L | 191.4M |
| Other Income/Expense | 2.7M |
| Interest Income | -0.6M |
| Pretax | 194.1M |
| Income Tax Expense | 30.8M |
| Net Income/Loss | 163.3M |
POINT Biopharma Global Inc. is a radiopharmaceutical company specializing in the development and commercialization of radioligands for cancer treatment. Its lead product candidates, including PSMA-targeted radioligands for prostate cancer and somatostatin-targeted radioligands for neuroendocrine tumors, are in advanced clinical trials. The company also has next-generation product candidates for prostate cancer and a fibroblast activation protein-a targeting program for multiple tumor types in preclinical studies. Additionally, it is leveraging CanSEEK technology sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited to develop innovative product candidates. POINT Biopharma generates revenue through the development and potential commercialization of its radioligand therapies.
